James E. Shields
Directeur/Membre du Conseil chez Allos Therapeutics, Inc.
Postes actifs de James E. Shields
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Directeur/Membre du Conseil | 05/09/2012 | - |
Historique de carrière de James E. Shields
Anciens postes connus de James E. Shields
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/05/2010 | 29/10/2012 |
Formation de James E. Shields
| University of Kentucky | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
Opérationnelle
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
| Director/Board Member | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
- Bourse
- Insiders
- James E. Shields
- Expérience
